Mylan Laboratories
Mylan Laboratories
HealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
3- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 9.47% over past five years.
- Company has a low return on equity of -5.06% over last 3 years.
Growth Rate
Profit & Loss
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 952 | 1,489 | 1,882 | 2,878 | 3,952 | 5,392 | 6,978 | 7,857 | 9,467 | 9,623 | 9,638 | 10,969 |
| Expenses | 797 | 1,172 | 1,611 | 2,342 | 3,177 | 4,392 | 6,100 | 7,293 | 8,485 | 8,079 | 7,811 | 9,219 |
| Operating Profit | 155 | 317 | 271 | 536 | 776 | 1,000 | 878 | 564 | 982 | 1,544 | 1,827 | 1,750 |
| OPM % | 16% | 21% | 14% | 19% | 20% | 19% | 13% | 7% | 10% | 16% | 19% | 16% |
| Other Income | -357 | 35 | 129 | 185 | 28 | 12 | 843 | 923 | 619 | 357 | 505 | 296 |
| Interest | 29 | 59 | 54 | 43 | 58 | 63 | 248 | 569 | 716 | 857 | 817 | 828 |
| Depreciation | 30 | 36 | 46 | 60 | 78 | 96 | 346 | 852 | 1,191 | 1,681 | 1,806 | 1,567 |
| PBT | -260 | 257 | 299 | 617 | 668 | 853 | 1,127 | 67 | -306 | -637 | -291 | -349 |
| Tax % | 15% | 26% | 29% | 25% | 30% | 39% | 25% | -99% | -56% | -26% | 14% | 17% |
| Net Profit | -298 | 189 | 214 | 466 | 469 | 520 | 845 | 134 | -135 | -470 | -331 | -408 |
| EPS in Rs | -19.3 | 12.22 | 13.68 | 29.79 | 30.01 | 33.23 | 54.04 | 8.59 | -8.62 | -30.03 | -21.16 | -26.11 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 31 | 31 | 31 | 31 | 31 | 31 | 37 | 38 | 49 | 49 | 49 | 49 |
| Reserves | 649 | 847 | 1,121 | 1,602 | 1,822 | 2,455 | 4,142 | 4,675 | 6,777 | 8,064 | 7,646 | 7,126 |
| Borrowings | 443 | 648 | 612 | 836 | 1,212 | 1,800 | 6,627 | 6,974 | 10,950 | 9,283 | 8,555 | 8,582 |
| Other Liabilities | 341 | 442 | 697 | 1,132 | 1,526 | 1,769 | 3,583 | 3,130 | 3,331 | 2,758 | 3,146 | 3,405 |
| Total Liabilities | 1,465 | 1,968 | 2,461 | 3,601 | 4,592 | 6,057 | 14,389 | 14,817 | 21,106 | 20,154 | 19,395 | 19,162 |
| Fixed Assets | 476 | 613 | 858 | 1,153 | 1,355 | 1,800 | 6,220 | 6,010 | 10,809 | 10,138 | 9,076 | 7,948 |
| CWIP | 115 | 148 | 133 | 77 | 110 | 131 | 1,021 | 941 | 805 | 762 | 367 | 328 |
| Investments | 232 | 232 | 177 | 262 | 245 | 54 | 156 | 163 | 0 | 0 | 0 | 0 |
| Other Assets | 642 | 975 | 1,292 | 2,108 | 2,882 | 4,072 | 6,992 | 7,703 | 9,492 | 9,254 | 9,953 | 10,886 |
| Total Assets | 1,465 | 1,968 | 2,461 | 3,601 | 4,592 | 6,057 | 14,389 | 14,817 | 21,106 | 20,154 | 19,395 | 19,162 |
Cash Flow
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 57 | 68 | 229 | 139 | 50 | 351 | 384 | 679 | 256 | 1,605 | 2,101 | 1,325 |
| Investing | -277 | -222 | -174 | -331 | -341 | -835 | -5,761 | -469 | -5,794 | -569 | -632 | -372 |
| Financing | 181 | 146 | -48 | 198 | 280 | 524 | 5,420 | -280 | 5,553 | -967 | -1,554 | -960 |
| Net Cash Flow | -39 | -8 | 7 | 6 | -11 | 40 | 44 | -70 | 16 | 70 | -85 | -8 |
| Free Cash Flow | -101 | -159 | -63 | -193 | -296 | -267 | -148 | 93 | -460 | 673 | 1,590 | 966 |
| CFO/OP | 48 | 32 | 113 | 53 | 25 | 65 | 77 | 132 | 29 | 105 | 116 | 76 |
Ratios
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 120 | 94 | 71 | 97 | 86 | 118 | 99 | 121 | 137 | 137 | 122 |
| Inventory Days | 240 | 195 | 252 | 253 | 229 | 223 | 243 | 289 | 289 | 267 | 311 | 311 |
| Days Payable | 166 | 139 | 142 | 155 | 151 | 144 | 159 | 150 | 140 | 121 | 167 | 156 |
| Cash Conversion Cycle | 163 | 177 | 205 | 169 | 175 | 164 | 203 | 239 | 270 | 283 | 281 | 278 |
| Working Capital Days | 131 | 149 | 132 | 131 | 133 | 145 | 165 | 207 | 226 | 235 | 245 | 235 |
| ROCE % | 15% | 24% | 18% | 27% | 27% | 30% | 14% | 2% | 1% | 2% | 3% | 3% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Mylan Laboratories insights
29 extracted metrics + investor summaries across FY08–FY19.
Documents
Frequently Asked Questions about Mylan Laboratories
What does Mylan Laboratories Ltd do?
Which sector does Mylan Laboratories Ltd belong to?
Company Information
Mylan Laboratories Limited,incorporated in India, listed on the Bombay Stock Exchange Limited, the company is engaged in the manufacture and trading of Pharmaceuticals
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MATRIXLABS.md for Mylan Laboratories Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.